Summary & Overview
HCPCS Level II M1192: Esophageal Squamous Cell Carcinoma, Established Diagnosis
HCPCS Level II code M1192 identifies patients with an established diagnosis of squamous cell carcinoma of the esophagus. This classification is used in clinical documentation and billing to denote the specific cancer histology and guide appropriate care pathways, utilization tracking, and payer adjudication. Nationally, accurate use of M1192 supports cancer registry alignment, oncology care coordination, and billing specificity that can affect coverage determinations and data reporting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how M1192 is applied across typical oncology sites of service, such as hospital inpatient units, outpatient oncology clinics, and specialized cancer centers.
Readers will find: a concise clinical context for squamous cell carcinoma of the esophagus; benchmarks and reporting considerations relevant to payer adjudication; common service settings where the code is used; and a summary of available modifiers and coding considerations. Where specific input fields were not provided, the report notes that data is not available in the input. This resource is intended to clarify the code’s clinical meaning and its role in national billing and documentation practices.
Billing Code Overview
HCPCS Level II code M1192 denotes patients with an existing diagnosis of squamous cell carcinoma of the esophagus. The service type for this code is diagnosis-based patient classification related to management or tracking of patients who have this specific esophageal cancer diagnosis. The typical site of service is hospital inpatient or outpatient oncology settings, including specialty cancer centers where patients with esophageal squamous cell carcinoma receive evaluation, follow-up, or treatment coordination.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a known diagnosis of squamous cell carcinoma of the mid‑to‑distal esophagus presents for evaluation and ongoing management. He reports progressive dysphagia to solids over several weeks, 10-lb weight loss, and occasional regurgitation. Prior staging included endoscopic biopsy confirming squamous cell carcinoma and cross-sectional imaging demonstrating a localized but potentially obstructive lesion without distant metastases. The clinical workflow typically begins with outpatient oncology and gastroenterology coordination: initial history and focused physical exam, review of histopathology and imaging, multidisciplinary tumor board discussion, and planning of interventions such as endoscopic dilation, stent placement, endoscopic ultrasound for staging, neoadjuvant chemoradiation, or palliative procedures.
On the day of service, the patient presents to an ambulatory endoscopy suite or hospital outpatient department. Pre-procedure nursing assessment and informed consent are completed. The gastroenterologist or thoracic surgeon performs diagnostic and/or therapeutic endoscopy under monitored anesthesia care or general anesthesia. Tissue sampling, tumor debulking, luminal stent placement, or dilation may occur depending on goals (definitive treatment vs palliation). Post-procedure recovery includes monitoring for complications such as perforation or bleeding, discharge instructions, coordination of oncology follow-up for chemoradiation if indicated, and documentation of procedure details, pathology, and treatment plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |